

Dr. Shri Jagat Prakash Nadda
The Minister of Health
Ministry of Health
155 - A, Nirman Bhavan
New Delhi – 110108
India

20 April 2016

Dear Minister,

Decision Letter for India Vaccine Support


I am writing in relation to India's proposal to Gavi, The Vaccine Alliance, for New Vaccines Support (NVS) for national scale up of pentavalent vaccines, submitted to Gavi in January 2014. **This letter is a revision of the Decision Letter sent to India on 27 March 2015 and replaces that letter.**

This revision reflects an additional number of doses of pentavalent vaccines (of 550,000 doses) that Gavi is able to provide due to obtaining a more favourable price. The revised information is specified in the Appendix A to this letter.

The Government of India understands that Gavi support for pentavalent vaccines in India is coming to an end and this is the last support before domestic procurement of the pentavalent vaccine.

Please do not hesitate to contact my colleague Carol Szeto cszeto@gavialliance.org if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

Cc:
PS, The Minister of Health and Family Welfare
PS, The Minister of Finance
Secretary, Ministry of Health and Family Welfare
Additional Secretary, MD NHM, Ministry of Health and Family Welfare
Joint Secretary, Ministry of Health and Family Welfare
Deputy Commissioner (MCH), Immunization and HSS, MoHFW
Deputy Commissioner (Immunization); MoHFW
Deputy Commissioner (UIP), MoHFW
WHO Country Representative
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

India Pentavalent Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: India				
2. Grant number: 1014-IND-04c-X / 15-IND-04c-X				
3. Date of Decision Letter: 20 April 2016				
4. Date of the Partnership Framework Agreement: 12 June 2015				
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID				
8. Programme duration¹: 2011 - 2015				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2011-2013	2014	2015	Total ²
Programme Budget (US\$)	US\$62,332,949 ³	US\$65,560,459	US\$137,106,592	US\$265,000,000
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2011-2013	2014	2015	
Number of Pentavalent vaccines doses		35,786,000	96,335,000	
Number of AD syringes				
Number of re-constitution syringes				
Number of safety boxes				
Annual Amounts (US\$)	US\$62,332,949 ⁵	US\$65,560,459	US\$137,106,592	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.


³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

12. Procurement agency: UNICEF
13. Self-procurement: Not applicable
14. Co-financing obligations: Not applicable
15. Operational support for campaigns: Not applicable
16. Additional reporting requirements: In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance (timing to be agreed with Secretariat).
17. Financial clarifications: Not applicable
18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

20 April 2016